Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Vazzano Joseph Walter reported reported sale transactions in this Form 4 filing.
Abeona Therapeutics Chief Financial Officer Joseph Walter Vazzano reported that 1,478 shares of common stock were withheld at $6.53 per share to satisfy tax withholding obligations upon vesting of restricted stock awards. After this tax-related withholding, he directly holds 492,079 shares.
Abeona Therapeutics Inc. filed a prospectus supplement updating a previously effective resale registration for up to 15,219,758 shares of common stock. The update reflects the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd., without changing the aggregate number of registered shares.
The company will not receive proceeds from any resale of shares by the selling stockholders, but will receive cash proceeds from any warrant exercises. Abeona's common stock trades on The Nasdaq Capital Market under the symbol ABEO, and the closing price on July 7, 2026 was $6.55 per share. Investors are directed to the incorporated risk factors and reports for a detailed discussion of risks.
Abeona Therapeutics Inc. Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 24,880 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, this sale was made to cover tax obligations tied to the vesting of restricted stock awards.
After this transaction, he directly holds 493,557 shares of Abeona common stock. The price reflects multiple trades executed between $6.86 and $7.04 per share.
Abeona Therapeutics Inc. chief executive officer Vishwas Seshadri reported an open-market sale of 67,971 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, the sale was made to cover tax obligations from vesting restricted stock awards, and he continued to hold 1,306,108 shares afterward.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.
The company notes this sale was made to cover tax obligations from vesting of restricted stock awards. After the sale, O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 12,606 shares of common stock at a weighted average price of $6.9637 per share. After this transaction, he directly holds 290,623 shares, indicating that only a small portion of his position was sold.
ABEO filed a Form 144 notice reporting proposed and recent transactions in its Common Stock. The filing lists 141,333 Restricted Stock Awards to be sold on 07/08/2026 and shows prior sales by Vishwas Seshadri of 24,428 shares on 06/08/2026 and 31,916 shares on 06/09/2026, with dollar values recorded alongside each prior sale.
Madhav Vasanthavada has notified plans to sell 12,606 shares of common stock through Stifel Nicolaus & Company on 07/09/2026 on Nasdaq, with an aggregate market value of $87,784.00. These shares relate to restricted stock awards acquired from the issuer on 07/08/2026, alongside prior common stock sales over the past three months.
ABEO submitted a Form 144 disclosing proposed dispositions of Common Stock. The filing lists a 07/08/2026 restricted stock award of 51,733 shares and prior proposed sales on 06/08/2026 and 06/09/2026 totaling 10,271 and 39,067 shares respectively with dollar amounts shown alongside each trade.
ABEO submitted a Form 144 disclosing proposed sales of Common Stock and recent restricted stock award activity. The filing lists 34,230 shares as Restricted Stock Awards dated 07/08/2026 and shows recent sales by Brendan O'Malley of 4,826 shares on 06/08/2026 and 6,305 shares on 06/09/2026. The filing references 56,995,144 shares outstanding as of 07/09/2026.